These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36866400)

  • 1. Metabolic associated fatty liver disease and cardiovascular risk: The expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society.
    Gorczyca-Głowacka I; Wełnicki M; Mamcarz A; Filipiak KJ; Wożakowska-Kapłon B; Barylski M; Szymański FM; Kasprzak JD; Tomasiewcz K
    Kardiol Pol; 2023; 81(2):207-214. PubMed ID: 36866400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of pneumococcal vaccination in reducing cardiovascular risk in cardiac patients: Expert opinion of the Prevention Committee of the Polish Cardiac Society supported by the Polish Vaccinology Society.
    Mamcarz A; Wełnicki M; Drożdż J; Grabowski M; Jankowski P; Kuchar E; Leszek P; Mitkowski P; Wysocki J
    Kardiol Pol; 2023; 81(10):1038-1046. PubMed ID: 37660388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of GLP-1 analogues in the treatment of diabetes in patients with cardiovascular diseases. The expert opinion of the Working Group of Cardiovascular Pharmacotherapy of the Polish Cardiac Society.
    Wełnicki M; Gorczyca-Głowacka I; Mamcarz A; Filipiak KJ; Wożakowska-Kapłon B; Barylski M; Szymański FM; Kasprzak JD; Grabowski M; Dzida G
    Kardiol Pol; 2022; 80(12):1286-1289. PubMed ID: 36601885
    [No Abstract]   [Full Text] [Related]  

  • 5. Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex.
    Matsubayashi Y; Fujihara K; Yamada-Harada M; Mitsuma Y; Sato T; Yaguchi Y; Osawa T; Yamamoto M; Kitazawa M; Yamada T; Kodama S; Sone H
    Cardiovasc Diabetol; 2022 Jun; 21(1):90. PubMed ID: 35655263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrotic Burden Determines Cardiovascular Risk among Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease.
    Han E; Lee YH; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee BW; Kang ES; Cha BS; Kim SU
    Gut Liver; 2022 Sep; 16(5):786-797. PubMed ID: 35321955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease.
    Chun HS; Lee M; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Lee YH; Kim JH; Kim SU
    Liver Int; 2023 Mar; 43(3):608-625. PubMed ID: 36585250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectively addressing cardiovascular risk in people with metabolic-dysfunction associated fatty liver disease: not yet ready for prime time!
    Koufakis T; Popovic DS; Papadopoulos C; Giouleme O; Doumas M
    Expert Opin Pharmacother; 2024 Feb; 25(2):123-126. PubMed ID: 38284365
    [No Abstract]   [Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.
    Lee H; Lim TS; Kim SU; Kim HC
    Hepatol Int; 2022 Dec; 16(6):1308-1317. PubMed ID: 36070124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-pill combinations (SPCs) and treatment of arterial hypertension in Poland. Expert consensus statement of the Polish Society of Hypertension and Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy.
    Tykarski A; Widecka K; Narkiewicz K; Wożakowska-Kapłon B; Gaciong Z; Grajek S; Grodzicki T; Januszewicz A; Wolf J; Prejbisz A; Kostka-Jeziorny K; Filipiak KJ
    Kardiol Pol; 2017; 75(12):1357-1367. PubMed ID: 29251761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of patients after heart valve interventions. Expert opinion of the Working Group on Valvular Heart Diseases, Working Group on Cardiac Surgery, and Association of Cardiovascular Interventions of the Polish Cardiac Society.
    Płońska-Gościniak E; Wojakowski W; Kukulski T; Gąsior Z; Grygier M; Mizia-Stec K; Hirnle T; Olszowska M; Tomkiewicz-Pająk L; Kasprzak JD; Suwalski P; Komar M; Bartuś S; Pysz P; Mizia-Szubryt M; Hryniewiecki TT
    Kardiol Pol; 2022; 80(3):386-402. PubMed ID: 35290659
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk factors for cardiovascular disease in patients with metabolic-associated fatty liver disease: a machine learning approach.
    Drożdż K; Nabrdalik K; Kwiendacz H; Hendel M; Olejarz A; Tomasik A; Bartman W; Nalepa J; Gumprecht J; Lip GYH
    Cardiovasc Diabetol; 2022 Nov; 21(1):240. PubMed ID: 36371249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiometabolic index: A new predictor for metabolic associated fatty liver disease in Chinese adults.
    Duan S; Yang D; Xia H; Ren Z; Chen J; Yao S
    Front Endocrinol (Lausanne); 2022; 13():1004855. PubMed ID: 36187093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
    Guerreiro GTS; Longo L; Fonseca MA; de Souza VEG; Álvares-da-Silva MR
    Hepatol Int; 2021 Apr; 15(2):380-391. PubMed ID: 33694066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Dysfunction-Associated Fatty Liver Disease Is Associated with the Risk of Incident Cardiovascular Disease: A Prospective Cohort Study in Xinjiang.
    Guo Y; Yang J; Ma R; Zhang X; Guo H; He J; Wang X; Cao B; Maimaitijiang R; Li Y; Peng X; Zhang S; Guo S
    Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.
    Chan WK; Tan SS; Chan SP; Lee YY; Tee HP; Mahadeva S; Goh KL; Ramli AS; Mustapha F; Kosai NR; Raja Ali RA
    J Gastroenterol Hepatol; 2022 May; 37(5):795-811. PubMed ID: 35080048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review and expert opinion on MAFLD, oxidative stress and multifunctional management.
    Angelico F; Alcantara-Payawal D; Rani RA; Mustafa N; Thongtang N; Chaiteerakij R; Bunchorntavakul C; Sukonthasarn A
    Drugs Context; 2024; 13():. PubMed ID: 38264403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.